ReviewFrontiers in immunology2022

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.

Nikeshan Jeyakumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.